



# HHS Public Access

Author manuscript

*Resuscitation*. Author manuscript; available in PMC 2019 March 01.

Published in final edited form as:

*Resuscitation*. 2018 March ; 124: 96–105. doi:10.1016/j.resuscitation.2018.01.013.

## Paediatric In-Hospital Cardiac Arrest: Factors associated with Survival and Neurobehavioural Outcome One Year Later

**Kathleen Meert, MD,**

Children's Hospital of Michigan Wayne State University 3901 Beaubien Boulevard Detroit, MI 48201, USA

**Russell Telford, MAS,**

University of Utah 295 Chipeta Wa P. O. Box 581289, Salt Lake City, UT 84158, USA

**Richard Holubkov, PhD,**

University of Utah 295 Chipeta Way P. O. Box 581289, Salt Lake City, UT 84158, USA

**Beth S. Slomine, PhD,**

Kennedy Krieger Institute Johns Hopkins University 707 North Broadway, Baltimore, MD 21205, USA

**James R. Christensen, MD,**

Kennedy Krieger Institute Johns Hopkins University 707 North Broadway Baltimore, MD 21205, USA

**John Berger, MD,**

Children's National Health System 111 Michigan Avenue, NW Washington, DC 20010, USA

**George Ofori-Amanfo, MD,**

The Children's Hospital at Montefiore 3415 Bainbridge Avenue, Bronx, NY, 10467, USA

**Christopher J.L. Newth, MD,**

Children's Hospital Los Angeles 4650 Sunset Boulevard Los Angeles, CA 90027, USA

**J. Michael Dean, MD, MBA,**

University of Utah 295 Chipeta Way, P. O. Box 581289 Salt Lake City, UT 84158, USA

**Frank W. Moler, MD, MS, and**

University of Michigan CS Mott Children's Hospital 1540 East Hospital, Drive Ann Arbor, MI 48109, USA

**for the Therapeutic Hypothermia after Paediatric Cardiac Arrest (THAPCA) Trial Investigators**

### Abstract

---

corresponding author: Kathleen Meert, MD.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Objective**—To investigate clinical characteristics associated with 12-month survival and neurobehavioural function among children recruited to the Therapeutic Hypothermia after Paediatric Cardiac Arrest In-Hospital trial.

**Methods**—Children (n=329) with in-hospital cardiac arrest who received chest compressions for 2 minutes, were comatose, and required mechanical ventilation after return of circulation were included. Neurobehavioural function was assessed using the Vineland Adaptive Behaviour Scale, second edition (VABS-II) at baseline (reflecting pre-arrest status) and 12 months post-arrest. Norms for VABS-II are 100 (mean)  $\pm$  15 (SD). Higher scores indicate better functioning. Outcomes included 12-month survival, 12-month survival with VABS-II decreased by 15 points from baseline, and 12-month survival with VABS-II  $\geq$  70.

**Results**—Asystole as the initial arrest rhythm, administration of  $>4$  adrenaline doses, and higher post-arrest blood lactate concentration were independently associated with lower 12-month survival; an adrenaline dosing interval of 3 to  $<5$  minutes and open chest compressions were independently associated with greater 12-month survival. Use of extracorporeal membrane oxygenation (ECMO) and higher blood lactate were independently associated with lower 12-month survival with VABS-II decreased by 15 points from baseline; open chest compressions was independently associated with greater 12-month survival with VABS-II decreased by 15 points. Asystole as the initial rhythm, use of ECMO, and higher blood lactate were independently associated with lower 12-month survival with VABS-II  $\geq$  70; open chest compressions was independently associated with greater 12-month survival with VABS-II  $\geq$  70.

**Conclusions**—Cardiac arrest and resuscitation factors are associated with long-term survival and neurobehavioural function among children who are comatose after in-hospital arrest.

### Keywords

In-hospital cardiac arrest; Paediatric; Neurobehavioural outcome

## INTRODUCTION

Cardiac arrest in children is an uncommon event that often leads to death or poor functional outcome among survivors. Cardiac arrest characteristics, interventions and outcomes differ between arrests occurring in in-hospital and out-of-hospital settings.<sup>1-3</sup> For example, physiologic monitoring, shorter response times, and the presence of skilled personnel are more typical of in-hospital than out-of-hospital arrests. Outcomes of in-hospital cardiac arrest are better than out-of-hospital arrest, yet only about a third of children with in-hospital arrest survive to discharge with good functional outcome.<sup>2, 4-5</sup>

Most in-hospital paediatric cardiac arrests occur in intensive care units (ICU).<sup>4</sup> Incidence rates are estimated at 1% to 3% for children in paediatric ICU<sup>6-8</sup> and 3% to 6% in cardiac ICU.<sup>9-11</sup> Epidemiologic studies of paediatric in-hospital cardiac arrest are primarily based on registries with voluntary reporting of data, or are retrospective single institution studies.<sup>4-5, 7-11</sup> Outcomes have generally been limited to mortality at hospital discharge and functional status among survivors using subjective measures such as the Paediatric Cerebral Performance Category (PCPC) scale.<sup>12</sup> A recent meta-analysis of paediatric cardiac arrest studies concluded there is a need for collaborative, prospective and potentially predictive

data on paediatric cardiac arrest to more clearly understand predictors of survival and long-term neurological outcome.<sup>13</sup>

The Therapeutic Hypothermia after Paediatric Cardiac Arrest (THAPCA) trials were two independent, parallel multicentre randomised controlled trials comparing the efficacy of therapeutic hypothermia versus therapeutic normothermia on survival with good neurobehavioural outcome one year after paediatric cardiac arrest in the in-hospital (THAPCA-IH) and out-of-hospital (THAPCA-OH) settings.<sup>14, 15</sup> Children included in the THAPCA trials were comatose, required mechanical ventilation after return of circulation, and were at high risk for neurologic injury. Neurobehavioural function was evaluated longitudinally in the THAPCA trials from baseline (reflecting pre-arrest status) through 12 months post-arrest using the Vineland Adaptive Behaviour Scales, second edition (VABS-II).<sup>16</sup> Therapeutic hypothermia, as compared to therapeutic normothermia, did not confer a significant benefit in survival with favourable functional outcome at 12 months post-arrest in either the in-hospital or out-of-hospital trial. We previously described clinical characteristics associated with 12-month survival and neurobehavioural function among children with out-of-hospital cardiac arrest recruited to the THAPCA-OH trial.<sup>17</sup> In this study, we investigate clinical characteristics associated with 12-month survival and neurobehavioural function among children with in-hospital cardiac arrest recruited to the THAPCA-IH trial.

## METHODS

### Design and setting

This study is a secondary analysis of data collected for the THAPCA-IH trial.<sup>14</sup> Thirty-seven children's hospitals in the United States, Canada, and the United Kingdom recruited children between September 1, 2009 and February 27, 2015. Details of the trial were previously published.<sup>14, 18–20</sup> The study was approved by the institutional review boards at all study sites and the Data Coordinating Centre at the University of Utah. Parental permission was obtained for all participants.

### Participants

Children eligible for the THAPCA-IH trial were >48 hours and <18 years of age, had a cardiac arrest that began within the walls of a hospital, received chest compressions for 2 minutes, and required mechanical ventilation after return of circulation. Major exclusion criteria included inability to be randomised within 6 hours of return of circulation, a Glasgow Coma Scale motor score of 5 or 6,<sup>21</sup> and a decision to withhold aggressive treatment. A full list of exclusion criteria was previously published.<sup>14, 18</sup> Of 2791 children meeting inclusion criteria, 329 were randomised to therapeutic hypothermia or therapeutic normothermia within 6 hours of return of circulation.

### Independent Variables

Data were collected by trained research coordinators at the time of study entry by medical record review and direct interaction with parents and clinicians. Data included child demographics, pre-existing conditions, body habitus, primary aetiology of arrest, presence of an intravenous catheter or endotracheal tube at the time of arrest, initial arrest rhythm,

duration of chest compressions, number of doses of adrenaline (epinephrine) during the arrest, adrenaline dosing interval, number of defibrillation attempts, use of open chest cardiac compressions, use of extracorporeal membrane oxygenation (ECMO) at the time of initiation of the THAPCA-IH study intervention, day and time of arrest, location of arrest within the hospital, previous ICU admissions during the hospitalisation in which the arrest occurred, and laboratory values recorded post-arrest but prior to the THAPCA-IH study intervention.

Child demographics included age, sex, race and ethnicity. Pre-existing conditions included cardiac, respiratory, neurologic, gastrointestinal, prenatal, pulmonary hypertension, and other conditions. Body habitus was evaluated using body mass index-for-age (BMI-for-age) percentiles for children  $\geq 2$  years of age, and weight-for-length percentiles for children  $< 2$  years of age.<sup>22</sup> If a subject's actual length was not available ( $n=15$ ), the median length-for-age adjusted for sex was used to determine the BMI-for-age or weight-for-length percentile. Children were considered obese if their BMI-for-age or weight-for-length was  $\geq 95^{\text{th}}$  percentile, and underweight if  $< 5^{\text{th}}$  percentile as recommended by the U.S. Centres for Disease Control and Prevention.<sup>22</sup> Primary aetiology of arrest was categorised as cardiovascular, respiratory, or other. Initial arrest rhythm was categorised as bradycardia, pulseless electrical activity (PEA), ventricular tachycardia/fibrillation (VF/VT), asystole, or unknown. The adrenaline dosing interval was defined as the duration of chest compressions divided by the total number of adrenaline doses administered during chest compressions. Day of arrest was categorised as weekday or weekend. Weekday was defined as Monday 12:00 AM to Friday 11:59 PM and weekend as Saturday 12:00 AM to Sunday 11:59 PM. Time of arrest was categorised as daytime or night time. Daytime was defined as 7:00 AM to 6:59 PM and night time as 7:00 PM to 6:59 AM. Location of arrest was categorised as emergency department, non-ICU hospital ward, ICU (including intermediate care), operating room, other clinical location (e.g., radiology suite) or non-clinical location (e.g., cafeteria).

## Outcomes

Neurobehavioural function was assessed using the VABS-II.<sup>16</sup> The VABS-II is a caregiver report measure of adaptive behaviour from birth to adulthood. Adaptive behaviour is defined as performance on daily life activities necessary for personal and social independence. VABS-II domains include communication, daily living, socialisation and motor skills. The number of tasks that can be performed in each domain is standardised for the child's age. In normative U.S. populations, the mean VABS-II is 100, and the standard deviation is 15. Higher scores indicate better functioning.

Outcomes included 12-month survival, 12-month survival with VABS-II decreased by  $\geq 15$  points from baseline, and 12-month survival with VABS-II  $\geq 70$ . Baseline VABS-II assessments (reflecting pre-arrest status) were completed by parents with the assistance of research coordinators at the sites within 24 hours of randomisation into the THAPCA-IH trial. Parents completed 12-month VABS-II assessments by telephone with interviewers from the Kennedy Krieger Institute.

## Statistical Analyses

Clinical characteristics were summarised using frequencies and percentages. Univariate associations between these characteristics and the outcomes were examined using either the chi-square test of no association or the Cochran-Armitage test for trend. In these associations, categories of “unknown” were excluded from the analysis only for the body habitus, number of adrenaline doses administered, adrenaline dosing interval, and number of defibrillation attempts. Associations between laboratory values and outcomes were assessed using the Wilcoxon rank-sum test. Logistic regression models were run for each outcome to estimate odds ratios and 95% confidence intervals. For these models, the clinical characteristics that had a univariate p-value <0.1 were entered into the model using a backward selection approach and only those with a p <0.05 were retained in the final model. All analyses were completed using SAS software v9.4 (Cary, NC).

## RESULTS

Of 329 children, 196 (59.6%) were male, 189 (57.4%) were White, and 165 (50.2%) were <1 year of age (Table 1). Two hundred and ninety-nine (90.9%) had at least one preexisting condition; 220 (66.9%) had a pre-existing cardiac condition (188 of which were congenital heart disease), 109 (33.1%) respiratory, 105 (31.9%) neurologic, 100 (30.4%) gastrointestinal, 86 (26.1%) prenatal, 20 (6.1%) pulmonary hypertension, and 148 (45.0%) other condition. Sixty-seven (20.4%) were underweight and 52 (15.8%) were obese.

Primary aetiology of arrest was cardiovascular for 214 (65.0%), respiratory for 100 (30.4%) and other for 15 (4.6%) (Table 2). Three hundred and one (91.5%) had intravenous access and 213 (64.7%) were intubated at the time of arrest. Initial arrest rhythm was bradycardia for 189 (57.4%), PEA for 69 (21.0%), VF/VT for 34 (10.3%) and asystole for 24 (7.3%). The duration of chest compressions was 15 minutes for 138 (41.9%), 15 to 30 minutes for 53 (16.1%) and >30 minutes for 138 (41.9%). The number of adrenaline doses was >4 for 156 (47.4%) and the adrenaline dosing interval was 3 to <5 minutes for 85 (25.8%). Sixty-seven (20.3%) received at least one defibrillation attempt. Fifty-six (17.0%) received open-chest compressions; of these 53 (94.6%) had a pre-existing cardiac condition, 51 (91.0%) had congenital heart disease, and 44 (78.5%) went on to receive ECMO. ECMO was utilised in a total of 180 (54.7%) at the time of initiation of the THAPCA-IH study intervention. Arrest occurred on a weekday for 272 (82.7%), and during the daytime for 226 (68.7%). Arrest occurred in an ICU for 202 (61.4%). Fifty-nine (17.9%) had a previous ICU admission during the hospitalisation in which the arrest occurred. Post-arrest laboratory values showed a median pH of 7.3 (Q<sub>1</sub>, Q<sub>3</sub> 7.3, 7.4), blood glucose concentration of 10.2 mmol/L (Q<sub>1</sub>, Q<sub>3</sub> 6.4, 15.2 mmol/L) (183 mg/dL (Q<sub>1</sub>, Q<sub>3</sub> 116, 274 mg/dL)) and blood lactate concentration of 6.6 mmol/L (Q<sub>1</sub>, Q<sub>3</sub> 2.8, 11.9 mmol/L) (Supplemental Material 1).

## Univariate Associations

The presence of pre-existing pulmonary hypertension was associated with lower 12-month survival, and pre-existing gastrointestinal condition was associated with lower 12-month survival with VABS-II 70 (Table 1). Asystole as the initial cardiac arrest rhythm was associated with lower 12-month survival and lower 12-month survival with VABS-II 70

(Table 2). Longer duration of chest compressions, >4 doses of adrenaline, and use of ECMO were associated with lower 12-month survival, 12-month survival with VABS-II decrease by 15 points from baseline, and 12-month survival with VABS-II 70; adrenaline dosing interval 3 to <5 minutes was associated with greater 12-month survival, 12-month survival with VABS-II decrease by 15 points, and 12-month survival with VABS-II 70. Open chest compressions was associated with greater 12-month survival with VABS-II decrease by 15 points from baseline and 12-month survival with VABS-II 70. Associations between post-arrest laboratory values and outcomes are shown in Supplemental Material 1. Lower blood pH and platelet count, and higher blood lactate concentration, aspartate aminotransferase activity, and international normalized ratio were associated with a lower frequency of all three outcomes. Blood glucose concentration was not associated with outcomes.

### Logistic Regression Models

Asystole as the initial arrest rhythm, administration of >4 adrenaline doses, and higher post-arrest blood lactate concentration were independently associated with lower 12-month survival; an adrenaline dosing interval of 3 to <5 minutes and open chest compressions were independently associated with greater 12-month survival (Table 3). Use of extracorporeal membrane oxygenation (ECMO) and higher blood lactate concentration were independently associated with lower 12-month survival with VABS-II decreased by 15 points from baseline; open chest compressions was independently associated with greater 12-month survival with VABS-II decreased by 15 points. Asystole as the initial rhythm, use of ECMO, and higher blood lactate concentration were independently associated with lower 12-month survival with VABS-II 70; open chest compressions was independently associated with greater 12-month survival with VABS-II 70.

## DISCUSSION

Our findings demonstrate several clinical characteristics that are independently associated with 12-month survival and neurobehavioural function among children who are comatose and require mechanical ventilation after in-hospital cardiac arrest irrespective of hypothermia treatment. These characteristics include asystole as the initial arrest rhythm, number of adrenaline doses, adrenaline dosing interval, use of open chest cardiac compressions, use of ECMO, and post-arrest blood lactate concentration.

Initial arrest rhythm has previously been associated with outcome after paediatric in-hospital and out-of-hospital cardiac arrest.<sup>23–26</sup> In a recent meta-analysis, initial non-shockable rhythms were found to have an average odds ratio for survival of 0.59 (95% CI 0.35–1.0) compared to shockable rhythms.<sup>13</sup> Our findings concur with prior research by demonstrating that an initial rhythm of asystole is independently associated with lower 12-month survival and 12-month survival with VABS-II 70, whereas VF/VT is independently associated with greater 12-month survival and 12-month survival with VABS-II 70. Although not evaluated in our study, prior research suggests that secondary shockable rhythms occurring during resuscitation may have worse outcomes than initial shockable rhythms.<sup>27</sup>

Number of adrenaline doses and adrenaline dosing interval were independently associated with 12-month survival in our study. The inverse relationship observed between number of

adrenaline doses and survival can be expected since more adrenaline doses are administered the longer cardiac arrest and resuscitation attempts persist. Longer duration of arrest results in a longer period of low cardiac output with increased potential for organ injury. Longer duration of arrest has been associated with decreased survival after both paediatric in-hospital and out-of-hospital arrest.<sup>3, 6, 9, 17, 24, 28</sup> Our findings also show an adrenaline dosing interval of 3 to <5 minutes results in greater 12-month survival than more or less frequent dosing. These findings support current American Heart Association (AHA) guidelines that recommend adrenaline administration at intervals of 3–5 minutes during resuscitation.<sup>29</sup> These findings are in contrast to those of a recent study based on data from the AHA Get with the Guidelines-Resuscitation registry suggesting longer adrenaline dosing intervals (>5 to <8 minutes and 8 to <10 minutes) improve survival to hospital discharge following paediatric in-hospital cardiac arrest.<sup>30</sup> It is possible that these conflicting findings are due to differences in the populations studied, with those in our study being more severely ill as suggested by post-arrest coma and the need for mechanical ventilation. Also, in the prior study, the dosing interval was calculated as the time between the first adrenaline dose and the resuscitation endpoint, divided by the number of adrenaline doses administered after the first dose.<sup>30</sup> In our study, the time of first adrenaline dose was not recorded; thus the dosing interval was calculated as the duration of chest compressions divided by the total number of adrenaline doses administered during compressions.

The use of open chest cardiac compressions was independently associated with greater 12-month survival and 12-month survival with good neurobehavioural function in our study. Open chest cardiac compressions are infrequent among children who have not had a recent median sternotomy. Although we did not record whether children who received open chest compressions had a sternotomy prior to cardiac arrest, we believe this is likely because most had a known pre-existing cardiac condition, primarily congenital heart disease. For children who have undergone cardiac surgery, reopening the chest may allow correction of mechanical or other reversible factors that led to the cardiac arrest.<sup>31</sup> Open chest compressions may also be a surrogate for having invasive hemodynamic monitoring in place to guide resuscitation since such monitoring would generally be performed in post-operative cardiac patients. Open chest compressions may increase arterial pressures, cardiac output, coronary perfusion pressure, return of spontaneous circulation and cerebral blood flow.<sup>31</sup> Our data show 78.5% of patients who had open chest compressions went on to ECMO. This suggests that open chest compressions did not adequately restore their circulation for the long-term, although it may have stabilized them enough to be placed on ECMO. Unfortunately, we are unable to determine the extent to which the association between open chest compressions and better outcome is due to patient characteristics (post-operative state, reversible causes, invasive monitoring) or hemodynamic benefits of directly compressing the heart; however, patient characteristics may be most likely. Current AHA guidelines suggest that open chest compressions may be helpful if employed during surgery when the chest or abdomen is already open, or in the early post-operative period after cardiothoracic surgery.<sup>32</sup>

ECMO was used at the time of initiation of study intervention in over half of the children recruited to the THAPCA-IH trial, and in this secondary analysis was found to be independently associated with lower 12-month survival with good neurobehavioural function. ECMO was either initiated during cardiopulmonary resuscitation (E-CPR) or after

return of spontaneous circulation but before study intervention. In either case, children receiving ECMO likely represent the more severely ill within this cohort, and therefore have worse outcomes than those not receiving ECMO. Prior research in children with cardiac arrest after cardiac surgery has similarly shown that the use of ECMO is independently associated with increased mortality at ICU discharge.<sup>33</sup> However, in a study that included only children with refractory in-hospital cardiac arrest (> 10 minutes), children receiving E-CPR had increased survival to hospital discharge and survival with favourable neurologic outcome based on PCPC scores compared to those receiving conventional CPR.<sup>34</sup>

Lactic acidosis after cardiac arrest results from inadequate oxygen delivery and anaerobic metabolism occurring both before and during the cardiac arrest. Hyperglycaemia and the administration of adrenaline during cardiac arrest are also believed to contribute to lactic acidosis. Elevated blood lactate levels in the 6 hours prior to arrest and in the first 24 hours post-arrest have been shown to be associated with hospital mortality after paediatric cardiac arrest.<sup>35–37</sup> Studies have also shown elevated blood lactate levels in the first 24 hours post-arrest to be associated with poor neurologic outcome based on PCPC scores.<sup>5, 36</sup> Findings from our study demonstrate that elevated blood lactate concentration after in-hospital cardiac arrest is associated with lower 12-month survival and worse neurobehavioural function among survivors based on VABS-II scores. We previously reported a similar association between post-arrest blood lactate concentration and 12-month survival and 12-month survival with VABS-II > 70 after out-of-hospital cardiac arrest using data from the THAPCA-OH trial.<sup>17</sup>

Strengths of our study include the multicentre design and the use of the VABS-II to measure neurobehavioural function at baseline and 12 months after in-hospital cardiac arrest. Limitations include the select sample of children recruited to the THAPCA-IH trial which limits the generalizability of our findings. Children recruited to the THAPCA-IH trial were comatose and required mechanical ventilation after cardiac arrest and therefore represent those at high risk of death or neurologic injury. However, these children are also the population for which better understanding of potential prognostic factors may be most useful to clinicians counselling families. Only 155 (47.4%) children survived to 12-months; thus, the number of children who had 12-month neurodevelopmental assessment with VABS-II is small. Other limitations include the large number of variables evaluated, as well as lack of data on some potentially important variables (e.g., time to first adrenaline dose).<sup>30, 38</sup> Variation in post-arrest management might also affect associations between cardiac arrest characteristics and outcomes. Missing data for some variables, such as laboratory values, limited our ability to include them in logistic regression models.

## CONCLUSIONS

For children who are comatose and require mechanical ventilation after in-hospital cardiac arrest, several factors including initial arrest rhythm, number of adrenaline doses and dosing interval, use of open chest cardiac compressions, use of ECMO, and post-arrest blood lactate concentration are associated with survival and neurobehavioural function at 1 year. Knowledge of these factors may be useful for improving resuscitation practices, identifying children at risk for poor long-term outcomes, and counselling families.



## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

**Lead Site - University of Michigan, Ann Arbor, Michigan**

**Principal Investigator (PI) (Scientific)** - Frank W. Moler, MD, MS

**Data Coordinating Centre (DCC), University of Utah, Salt Lake City, Utah.**

**Principal Investigator DCC** - J. Michael Dean, MD, MBA

**Lead Biostatistician** - Richard Holubkov, PhD

**Outcome Centre, Kennedy Krieger Institute, Baltimore, Maryland. Academic affiliation with Johns Hopkins University, School of Medicine**

James R. Christensen, MD, Beth S. Slomine, PhD

### Executive Committee

|                       |                         |                            |
|-----------------------|-------------------------|----------------------------|
| F. Moler, MD, MS,     | PI (Scientific)         | University of Michigan     |
| J. M. Dean, MD, MBA   | PI (DCC)                | University of Utah         |
| R. Holubkov, PhD      | Biostatistician         | University of Utah         |
| K. Meert, MD          | Critical Care           | Wayne State University     |
| J. Hutchison, MD      | Critical Care           | University of Toronto      |
| V. Nadkarni, MD       | Critical Care           | University of Pennsylvania |
| S. Shankaran, MD      | Neonatology             | Wayne State University     |
| F. Silverstein, MD    | Neurology               | University of Michigan     |
| J. Christensen, MD    | Rehabilitation Medicine | Kennedy-Krieger Institute  |
| V. Pemberton, RNC, MS | NHLBI                   | NIH                        |
| C. Nicholson, MD, MS  | NICHHD, CPCCRN          | NIH                        |
| T. Singh Weik, DrPH   | MCHB EMSC, PECARN       | HRSA                       |

Sites and research teams - contributors

We acknowledge the contributions of the following sites and individuals who made the THAPCA-IH Trial possible.

Site principal investigators (PI), Sub-investigators (Sub-I), Clinical research coordinators (CRC), and Research Assistant (RA).

The Children's Hospital of Alabama, Birmingham, AL

J. Alten (PI), S. Borasino (Sub-I), K. Hock (CRC), K. Sewell (CRC), L. Dure (Neurologist), D. Marullo (Psychologist)

Arkansas Children's Hospital, Little Rock, AR

R. Sanders (PI), P. Prodhon (Sub-I), G. Hefley (CRC)

Phoenix Children's Hospital, Phoenix, AZ

H. J. Dalton (PI), S. Buttram (PI), K. Wai (Sub-I), A. La Bell (CRC), C. Bliss (CRC), D. Liss (CRC), A. Ortiz (CRC), C. Downhour (CRC), K. Williams (Neurologist), M. Lavoie (Psychologist), V. Bordes-Edgar (Psychologist)

Diamond Children's Medical Centre, Tucson, AZ

A. Theodorou (PI), K. Typpo (Sub-I), C. Wells (CRC), J. Deschenes (CRC)

Children's Hospital Los Angeles, Los Angeles, CA

C. Newth (PI), L. Nelson (Sub-I), S. Rubin (Sub-I), R. Bart (Sub-I), T. Deakers (Sub-I), A. Bhalla (Sub-I), R. Khemani (Sub-I), B. Markovitz (Sub-I), J. DiCarlo (Sub-I), P. Ross (Sub-I), C. Herrington (Sub-I), W. Wells (Sub-I), R. Kim (Sub-I), L. Nelson (Sub-I), M. Villa (CRC), F. Fajardo (CRC), J. Kwok (CRC), J. Serrano (CRC), J. Valentine (CRC), J. Terry (CRC), A. Yamakawa (CRC), S. Briones (CRC), S. Cauley (RN), A. Briseno (RN), C. Young (RN), M. Nyc (CRC), T. Rosser (Neurologist), J. Gold (Psychologist), R. Engilman (Psychometrician)

Children's Hospital of Orange County, Orange, CA

A. Schwarz (PI), J. Haykawa (Sub-I), O. Vargas-Shiraishi (CRC), A. Galion (Neurologist)

Loma Linda University Children's Hospital, Loma Linda, CA

M. Mathur (PI), G. Oei (Sub-I), J. Newcombe (CRC), A. Pinto (CRC), S. Ashwal (Neurologist), D. Michelson (Neurologist), J. Pivonka-Jones (Neuropsychologist)

Mattel Children's Hospital UCLA, Los Angeles, CA

R. Harrison (PI), R. Kelly (Sub-I), A. Madikians (Sub-I), M. Federman (Sub-I), A. Yamakawa (CRC), M. Nyc (CRC), S. Briones (CRC), M. Villa (CRC), J. Kwok (CRC), J. Serrano (CRC), J. Valentine (CRC)

University of California, San Francisco Benioff Children's Hospital, San Francisco, CA

P. McQuillen (PI), S. Tabbutt (Sub-I), L. Haeusslein (CRC), S. Strong (CRC), H. Glass (Neurologist), B. Johnson (Psychologist), B. Loomis (Psychologist), D. Gano (Neurologist)

Hospital for Sick Children, Toronto, ON, Canada

J. Hutchison (PI), S. Schwartz (Sub-I), A. Guerguerian (Sub-I), K. Boutis (Sub-I), D. Clark (CRC), J. Van Huyse (CRC), K. Fusco (CRC), K. McBain (CRC), A. Krancevic (CRC), L. Toller (CRC), R. Gaitero (CRC), S. Furness (CRC), R. Askalan (Neurologist), C. Hahn (Neurologist), R. Sananes (Psychologist)

Children's Hospital Colorado, Aurora, CO

E. Dobyms (PI), J. Albietz (Sub-I), L. Rappaport (Sub-I), E. Jewett (CRC), T. Wilson (CRC), B. Wathen (CRC), M. Dix (CRC), J. Allen (CRC), T. Garling (CRC), D. DiDomenico (CRC), D. Loyola (CRC), T. Bernard (Neurologist), J. Dise-Lewis (Psychologist)

All Children's Hospital, Tampa, FL

A. Stock (PI), K. Battick (CRC), A. Fleming (CRC), J. Hanson (CRC), M. Macogay (CRC), K. Martin (CRC), K. Burger (CRC)

Children's Healthcare of Atlanta, Atlanta, GA

N. Pham (PI), N. Chanani (Sub-I), K. Walson (Sub-I), J. Sturm (Sub-I), W. Mahle (Sub-I), M. Wolf (Sub-I), C. Stone (CRC), A. Wellons (CRC), S. Meisner (CRC), E. Hoar (CRC), K. Fields (CRC), S. Gentry (CRC), L. Smitley (CRC), L. McMaster (CRC), R. Willis (CRC), P. Holt (Neurologist), B. Weissman (Neurologist), A. Alexander (Psychologist), A. Johnson (Psychologist)

Riley Hospital for Children, Indianapolis, IN

M. Rigby (PI), R. Lutfi (PI), C. Rider (CRC), J. Liford (CRC), G. Thomas (CRC), D. Sokol (neurologist), B. McDonald (psychologist)

Anne and Robert Lurie Children's Hospital of Chicago, Chicago, IL

D. Goodman (PI), C. Smith (PI), E. Powell (Sub-I), S. Shah (CRC), J. Chiambrietti (CRC), C. Lutz (CRC), C. Vitt (CRC), L. Jackson-McCarthy (CRC), N. Leannais (CRC), M. Wainwright (Neurologist), J. Goldstein (Neurologist), C. Weil (Psychologist)

Kosair Charities Paediatric Clinical Research Unit, Department of Paediatrics, University of Louisville and the Kosair Children's Hospital, Louisville, KY

M. Porter (PI), J. Sullivan (Sub-I), K. Orman (Sub-I), E. Owen (Sub-I), K. Potter (Sub-I), E. Peterson (Sub-I), M. Ruppe (Sub – I), J. Berkenbosch (Sub-I), M. McDonald (Sub-I), V. Montgomery (Sub-I), A. Calhoun (Sub-I), M. Thomas (CRC), A. Michael (CRC), J. Nason (CRC), K. Kernen (CRC), L. Good (CRC, V. Puri (Neurologist), L. Sears (Psychologist)

Johns Hopkins Children's Center, Baltimore, MD

U. Bhalala (PI), J.K. Lee (PI), M. Bembea (PI), D. Shaffner (Sub-I), A. Walker (Sub-I), B. Shivakumar (CRC) M. Shackelford (CRC), A. Larson (CRC), J. Jamrogowicz (CRC), J. Kim (CRC), R. Felling (Neurologist), B. Slomine (Psychologist)

Outcome Center, Kennedy Krieger Institute, Baltimore, MD

J.R. Christensen (Site PI), B.S. Slomine (Site Co-Investigator), E. DeMatt (Telephone Interviewer), M. Talley (Telephone Interviewer), C. Rodweller (Telephone Interviewer)

Children's Hospital of Michigan, Detroit, MI

K. Meert (PI), S. Heidemann (Sub-I), J. Clark (Sub-I), A. Pawluszka (CRC), R. Delius (Sub-I), H.L. Waters III (Sub-I), M. Lulic (RA), L. Sivaswamy (Neurologist), S. Horman (Psychometrician), L. Chiodo (Psychologist)

C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI

F. Moler (PI), M. Gaies (Sub-I), M. Weber (CRC), J. Reske (CRC), L. Conlin (CRC), F. Silverstein (Neurologist), M. Carlson (Neurologist), S. Warschausky (Psychologist), T. Behnke (Program Administrator), D. Poszywak (Procurement Subcontract Administrator)

*"Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Numbers UL1 RR 024986 and UL1 TR 000433. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."*

Children's Hospitals and Clinics of Minnesota, Minneapolis, MN

J. Nowak (PI), E. Zielinski (CRC), A. Doucette (CRC), A. Overman (CRC), C. Leonard (CRC), E. Gilles (Neurologist), P. Huszar (Neurologist), M. Troy (Psychologist), J. Alden (Psychologist)

Washington University, St. Louis, MO

J. Pineda (PI), P. Oren (Sub-I), M. Shoykhet (Sub-I), S. Friess (Sub-I), K. Guilliams (Sub-I), A. Gazit (Sub-I), A. Doctor (Sub-I), T. Day (CRC), T. Hicks (CRC), L. Barganier (CRC), E. Fish (CRC), L. Toennies (CRC), P. Thurst (CRC), S. Blankenship (CRC), M. Noetzel (Neurologist), K. Guilliams (Neurologist), D. White (Psychologist).

Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number U54 HD087011 to the Intellectual and Developmental Disabilities Research Centre at Washington University. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

Morgan Stanley Children's Hospital/Columbia University Medical Center New York, NY

C. Schleien (PI), N. Talathoti (CRC), N. Sidhu (Neurologist), V. Hinton (Psychologist)

University of Rochester Medical Center/Golisano Children's Hospital, Rochester, NY

E. W. van der Jagt, (PI), E. R. Taillie (CRC), E. B. Nazarian (Sub-I), L. E. Daugherty (Sub-I), J. L. Mulbury (Neurologist), H. R. Adams (Psychologist)

Duke Children's Hospital, Durham, NC

G. Ofori-Amanfo (PI), K. Rehder (PI), S. Wrenn (CRC), T. Uhl (CRC), C. Milleson (CRC), E. Smith (Neurologist), K. Gustafson (Psychologist), S. Asbeck (Psychologist), W. Gallentine (Neurologist)

Nationwide Children's Hospital, Columbus, OH

E. Lloyd (PI), M. Hall (Sub-I), N. Khan (Sub-I), J. Frazier (Sub-I), Daniel Cohen (Sub-I), J. Haines (CRC), K. Carter (CRC), L. Bird (CRC), W. Lo (Neurologist), K. Yeates (Psychologist), K. Morfing (Psychologist), M. Ginn (Psychologist)

Cincinnati Children's Hospital, Cincinnati, OH

D. Wheeler (PI), E. Beckman (CRC), S. Banschbach (CRC), M. Monaco (CRC), K. Howard (CRC)

Rainbow Babies and Children's Hospital, Cleveland, OH

K. Lidsky (PI), S. Bergant (CRC), A. Browning (CRC), J. Haky (CRC)

Penn State Children's Hospital, Hershey, PA

N. Thomas (PI), A. Shelly (CRC), J. Vallati (CRC), P. Carper (CRC), D. Spear (CRC), A. McMonagle (CRC), J. Stokes (CRC), H. Watts (CRC), W. Trescher (Neurologist), C. Flaherty-Craig (Psychologist)

Children's Hospital of Philadelphia, Philadelphia, PA

A. Topjian (PI), R. Berg (Sub-I), V. Nadkarni (Sub-I), A. Zuppa (Sub-I), S. Friess (Sub-I), J. Fitzgerald (Sub-I), P. Meaney (Sub-I), E. Alpern (EM Sub-I), M. DiLiberto (CRC), C. Twelves (CRC), S. McGowan (CRC), M. Sisko (CRC), B. Park (CRC), R. Ichord (Neurologist), J. Radcliffe (Psychologist), N. Hattiangadi Thomas (Psychologist), K. Friedman (Psychologist), A. Sullivan (Psychometrist)

*The project described was supported by the National Centre for Research Resources and the National Centre for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.*

University of Pittsburgh Medical Center, Pittsburgh, PA

E. Fink (PI), R. Clark (Planning Committee), M. Bell (Sub-I), R. Munoz (Sub-I), A. Abraham (CRC), R. Bell (CRC), D. Cummings (Neurologist) S. Beers (Psychologist), H. Feldman (Psychologist)

University of Tennessee Health Science Center, Memphis, TN

S. Shah (PI), K. Anand (Sub-I), C. Woodward (Sub-I), A. Hickerson (CRC), B. Moore (CRC), A. Nico West (CRC), M. Grandberry (CRC), N. Shah (Neurologist), N. Clanton (Psychologist), L. Berkelhammer (Psychologist), O. King (Psychologist), A. Huling (Psychologist), L. White (Psychologist)

Children's Medical Center Dallas, University of Texas Southwestern Medical School, Dallas, TX

J. Koch (PI), P. Okada (Sub-I), D. Miles (Sub-I), L. Raman (Sub-I), M. Green (Sub-I), E. Golson (CRC), A. Jones (CRC), D. Kelly (CRC), T. Plumb (CRC), K. Van de Bruinhorst (CRC), M. Dowling (Neurologist), P. Stavinoha (Psychologist), A. Hernandez (Psychometrician)

University of Texas Health Sciences Center at San Antonio, San Antonio, TX

T. Wu (PI), C. Bauerfeld (Sub-I), H. Dibrell (CRC), S. Atkinson (Neurologist), L. O'Donnell (Psychologist), J. Eubanks (Psychologist)

Texas Children's Hospital, Houston, TX

L. Shekerdeman (PI), M. Goldsworthy, (CRC)

Data Coordinating Center (DCC), University of Utah, Salt Lake City, UT

J. M. Dean (PI), R. Holubkov (Biostatistician), B. Browning (Program Director), M. Gildea (Program Director), R. Kuhn (Project Manager), K. Register (Project Manager), N. Tattersall (Project Manager), A. Vrem (Project Manager), K. Jacobsen (Project Manager), A. Webster (Biostatistician), A. Clark (Biostatistician), K. Page (Biostatistician), J. Wang (Biostatistician), R. Telford (Biostatistician), L. Herrera (Data Manager), J. Yearley (Director Data Management), R. Enriquez (Director Information Technology/Information Systems), D. Demarco (Data Center Manager), M. Virtosu (Senior Software Engineer), S. Su (Senior Software Engineer), J. Bell (Senior Database Developer), S. Zupan (PECARN Program Director), J. Burr (CPCCRN Program Director), S. Simmons

(Information Coordinator), V. McKean (Administrative Assistant), C. Traeden (Administrative Assistant), H. Nitsuma (Administrative Assistant), B. Marron (Administrative Assistant)

Primary Children's Hospital, Salt Lake City, UT

K.S. Bennett (PI), J. Sweney (PI), J. Lilley (CRC), S. Bjerregaard (CRC), K. Jacobsen (CRC), A. Watson, (CRC), D. Stephen (CRC), M. Delacruz (CRC), K. Cooley (CRC), N. Kwendakwema (CRC), B. Ameel (CRC), G. Jensen (CRC), M. Metcalf (CRC), R. Cole (CRC), R. Moore (CRC), M. Sweney (Neurologist), D. Morita (Neurologist), R. Burr (Psychologist), T. Bennett (Sub-I), J. Henricksen (Sub-I), E. Hirshberg (Sub-I), A. Hubbard (Sub-I), G. Larsen (Sub-I), B. Poss (Sub-I), M. Schober (Sub-I), R. Dixon (Sub-I), J. Workman (Sub-I), J. Woods (Sub-I)

Seattle Children's Hospital, Seattle, WA

J. Zimmerman (PI), J. McGuire (Sub-I), R. Farris (Sub-I), O. Yanay (Sub-I), L. Smith (Sub-I), T. Brogan (Sub-I), S. Hamilton (CRC), R. Barker (CRC), C. Greeley (CRC), C. Cheng (CRC), M. Sadler Greever (CRC), S. Gospe (Neurologist), C. Amlie-Lefond (Neurologist), D. Breiger (Psychologist), A. Paolozzi (Psychologist)

Children's National Medical Center, Washington, DC

J. Berger (PI), D. Wessel (Sub- I), M. Sharron (Sub-I), S. Basu (Sub-I), A. Wratney (Sub-I), N. Dean (Sub-I), J. Reardon (CRC), E. Tomanio (CRC), F. Ramos (RA), B. Tadesse (RA), M. Menicucci (CRC), J. Carpenter (Neurologist), S. Swanson (Psychologist), T. Brennan (Psychologist), P. Glass (Psychologist), B. Malek (Psychologist), M. Mintz (Psychologist)

Our follow ups were conducted in the Clinical Research Center which is supported by NIH P30HD040677

Medical College of Wisconsin, Milwaukee, WI

M. T. Meyer (PI), M. Wakeham (Sub-I), S. Hanson (Sub-I), Marc Gorelick (Sub-I), M. Christensen (CRC), D. Triscari (CRC), B. Horn (CRC), K. Murkowski (CRC), K. Hecox (Neurologist), C. Brosig (Psychologist)

UK Sites

Alder Hey Children's Hospital, Liverpool, United Kingdom

P. Baines (PI), N. Shetty (Sub-I), A. Wood (CRC), E. Scott (CRC), S. Siner (CRC), L. Walsh (CRC)

Birmingham Children's Hospital, Birmingham, United Kingdom

B. Scholefield (Lead UK Study PI), A. Jones (Lead UK Study CRC), T. Cameron (CRC), A. Mohammed Ali (Sub-I), K. Morris (Sub-I), I. Zafurallah (Sub-I), D. Ellis (Sub-I), A. Top (Sub-I), C. McTernan (CRC), J. Menzies (CRC)

Bristol Royal Hospital for Children, Bristol, United Kingdom

M. Schindler (PI), S. George (CRC), S. Potter (CRC), H. Smee (CRC)

Great Ormond Street Hospital, London, United Kingdom

S. Skellett (PI), T. Thiruchelvam (PI), A.J. Petros (Sub-I), M.J. Peters (Sub-I) P. Payne (CRC), D. Goodacre (CRC), A. Jones (CRC)

Evelina London Children's Hospital, London, United Kingdom

A. Nyman (PI), J. Harris (CRC), P. Wellman (CRC), H. Belfield (CRC)

Royal Manchester Children's Hospital, Manchester, United Kingdom

S. Playfor (PI), P. Hudnott (CRC), C. O'Riordan (CRC)

University Hospital Southampton, Southampton, United Kingdom

J. Pappachan (PI), R. Fowler (CRC), R. Ensom (CRC), K. Morton (CRC)

Clinical Research Networks

#### Paediatric Emergency Care Applied Research Network (PECARN)

*PECARN Steering Committee:* P. Dayan, Chair; E. Alpern, L. Bajaj, K. Brown, D. Borgiali, J. Chamberlain, J. M. Dean, M. Gorelick, D. Jaffe, N. Kupperman, M. Kwok, R. Lichenstein, K. Lillis, P. Mahajan, R. Maio, D. Monroe, L. Nigrovic, E. Powell, A. Rogers, R. Ruddy, R. Stanley, M. Tunik

*MCHB/EMSC liaisons:* D. Kavanaugh, H. Park.

*Central Data Management and Coordinating Center (CDMCC):* J. M. Dean, H. Gramse, R. Holubkov, A. Clark, R. Enriquez, C. Olson, S. Zuspan

*Feasibility and Budget Subcommittee (FABS):* K. Brown, S. Goldfarb, Co-Chairs; E. Crain, E. Kim, S. Krug, D. Monroe, D. Nelson, M. Berlyant, S. Zuspan

*Grants and Publications Subcommittee (GAPS):* M. Gorelick, Chair; L. Alpern, J. Anders, D. Borgiali, L. Babcock Cimpello, A. Clark, G. Foltin, F. Moler, K. Shreve

*Protocol Review and Development Subcommittee (PCRADS):* D. Jaffe, Chair; J. Chamberlain, P. Dayan, J.M. Dean, R. Holubkov, L. Nigrovic, E. Powell, K. Shaw, R. Stanley, M. Tunik

*Quality Assurance Subcommittee (QAS):* K. Lillis, Chair; E. Alessandrini, S. Blumberg, R. Enriquez, R. Lichenstein, P. Mahajan, R. McDuffie, R. Ruddy, B. Thomas, J. Wade *Safety and Regulatory Affairs Subcommittee (SRAS):* W. Schalick, J. Hoyle, Co-Chairs; S. Atabaki, K. Call, H. Gramse, M. Kwok, A. Rogers, D. Schnadower, N. Kuppermann

#### Collaborative Pediatric Critical Care Research Network (CPCCRN)

C.J. Newth, R. Harrison, K. Meert, S. Heidemann, T. Shanley, F. Moler, A. Zuppa, R. Berg, J. Berger, D. Wessel, H. Dalton, M. Pollack, M. Bell, J. Carcillo, A. Clark, R. Holubkov, J.M. Dean, and C. Nicholson for the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) Collaborative Pediatric Critical Care Research Network (CPCCRN).

#### DSMB

A. Zaritsky, MD (DSMB Chair), (Paediatrics), Eastern Virginia Medical School, Norfolk, VA

A. Atz, MD, (Pediatric Cardiology and Intensive Care), Medical University of South Carolina, Charleston, SC

D.V. Glidden, PhD, (Biostatistics), University of California San Francisco, San Francisco, CA

J. Lantos, MD, (Bioethics), Children's Mercy Kansas City, Kansas City, MO

M. Gausche-Hill, MD, (Pediatric Emergency Medicine/EMS), Harbor-UCLA Medical Center, Torrance, CA

G. L. Holmes, MD, (Neurology), University of Vermont, College of Medicine, Burlington, VT

R. Ehrenkranz, MD, (Neonatal-Perinatal Medicine), Yale University School of Medicine, New Haven, CT

National Heart, Lung, and Blood Institute, Bethesda, MD

V. Pemberton, J. Kaltman, J. Troendle, G. Pearson

#### ROLE OF FUNDING SOURCE

This work is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or National Institutes of Health.

#### CONFLICT OF INTEREST STATEMENT

Primary support for the conduct of the THAPCA-IH Trial was funding from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute, Bethesda, MD. HL094345 (FWM) and HL094339 (JMD). Additional support from the following federal planning grants contributed to the planning of the THAPCA Trials: NIH, *Eunice Kennedy Shriver* National Institute of Child Health and Development (NICHD), Bethesda, MD. HD044955 (FWM) and HD050531 (FWM). In part support was obtained from the participation of the following research networks: Paediatric Emergency Care Applied Research Network (PECARN) from cooperative

agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008; and the Collaborative Paediatric Critical Care Research Network (CPCCRN) from cooperative agreements (U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012 and U01HD049934. At several centres (as indicated below), clinical research support was supplemented by the following grants or Cooperative Agreements: UL1 RR 024986, UL1 TR 000433, U54 HD087011, UL1TR000003, and P30HD040677. The National Emergency Medical Services for Children (EMSC) Data Analysis Resource Centre Demonstration grant U07MC09174 provided for educational study materials.

## References

1. Moler FW, Meert K, Donaldson AE, et al. In-hospital versus out-of-hospital pediatric cardiac arrest: a multicenter cohort study. *Crit Care Med.* 2009; 37:2259–67. [PubMed: 19455024]
2. Meert KL, Donaldson A, Nadkarni V, et al. Multicenter cohort study of in-hospital pediatric cardiac arrest. *Pediatr Crit Care Med.* 2009; 10:544–3. [PubMed: 19451846]
3. Moler FW, Donaldson AE, Meert K, et al. Multicenter cohort study of out-of-hospital pediatric cardiac arrest. *Crit Care Med.* 2011; 39:141–49. [PubMed: 20935561]
4. Berg RA, Sutton RM, Holubkov R, et al. Ratio of PICU versus ward cardiopulmonary resuscitation events is increasing. *Crit Care Med.* 2013; 41:2292–97. [PubMed: 23921270]
5. Del Castillo J, Lopez-Herce J, Matamoros M, et al. Long-term evolution after in-hospital cardiac arrest in children: Prospective multicenter multinational study. *Resuscitation.* 2015; 96:126–34. [PubMed: 26296583]
6. Berg RA, Nadkarni VM, Clark AE, et al. Incidence and outcomes of cardiopulmonary resuscitation in PICUs. *Crit Care Med.* 2016; 44:798–808. [PubMed: 26646466]
7. Gupta P, Tang X, Gall CM, Lauer C, Rice TB, Wetzel RC. Epidemiology and outcomes of in-hospital cardiac arrest in critically ill children across hospitals of varied center volume: A multicenter analysis. *Resuscitation.* 2014; 85:1473–79. [PubMed: 25110249]
8. de Mos N, van Litsenburg RR, McCrindle B, Bohn DJ, Parshuram CS. Pediatric in-intensive-care-unit cardiac arrest: incidence, survival, and predictive factors. *Crit Care Med.* 2006; 34:1209–25. [PubMed: 16484906]
9. Gupta P, Wilcox A, Noel TR, et al. Characterizing cardiac arrest in children undergoing cardiac surgery: A single center study. *J Thorac Cardiovasc Surg.* 2017; 153:450–8. [PubMed: 27866783]
10. Gupta P, Jacobs JP, Pasquali SK, et al. Epidemiology and outcomes after in-hospital cardiac arrest after pediatric cardiac surgery. *Ann Thorac Surg.* 2014; 98:2138–44. [PubMed: 25443018]
11. Parra DA, Totapally BR, Zahn E, et al. Outcome of cardiopulmonary resuscitation in a pediatric cardiac intensive care unit. *Crit Care Med.* 2000; 28:3296–300. [PubMed: 11008995]
12. Fiser DH. Assessing the outcome of pediatric intensive care. *J Pediatr.* 1992; 121:68–74. [PubMed: 1625096]
13. Phillips RS, Scott B, Carter SJ, et al. Systematic review and meta-analysis of outcomes after cardiopulmonary arrest in childhood. *PLOS One.* 2015; 10(6):e0130327.doi: 10.1371/journal.pone.0130327 [PubMed: 26107958]
14. Moler FW, Silverstein FS, Holubkov R, et al. Therapeutic hypothermia after in-hospital cardiac arrest in children. *N Engl J Med.* 2017; 376:318–29. [PubMed: 28118559]
15. Moler FW, Silverstein FS, Holubkov R, et al. Therapeutic hypothermia after out-of-hospital cardiac arrest in children. *N Engl J Med.* 2015; 372:1898–908. [PubMed: 25913022]
16. Sparrow, S., Cicchetti, D., Balla, D. *Vineland Adaptive Behavior Scales.* 2nd. Minneapolis: Pearson Assessment; 2005.
17. Meert KL, Telford R, Holubkov R, et al. Pediatric out-of-hospital cardiac arrest characteristics and their association with survival and neurobehavioral outcome. *Pediatr Crit Care Med.* 2016; 17:e543–50. [PubMed: 27679965]
18. Moler FW, Silverstein FS, Meert KL, et al. Rationale, timeline, study design, and protocol overview of the therapeutic hypothermia after pediatric cardiac arrest trials. *Pediatr Crit Care Med.* 2013; 14:e304–15. [PubMed: 23842585]
19. Holubkov R, Clark AE, Moler FW, et al. Efficacy outcome selection in the therapeutic hypothermia after pediatric cardiac arrest trials. *Pediatr Crit Care Med.* 2015; 16:1–10. [PubMed: 25268768]

20. Pemberton VL, Browning B, Webster A, Dean JM, Moler FW. Therapeutic hypothermia after pediatric cardiac arrest trials: the vanguard phase experience and implications for other trials. *Pediatr Crit Care Med*. 2013; 14:19–26. [PubMed: 23295834]
21. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale *Lancet*. 1974; 2(7872):81–4. [PubMed: 4136544]
22. Centers for Disease Control and Prevention. Division of Nutrition, Physical Activity, and Obesity: Growth chart training. (Accessed 30 August 2017, at <http://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/>)
23. Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. *JAMA*. 2006; 296:50–7.
24. Zeng J, Qian S, Zheng M, Wang Y, Zhou G, Wang H. The epidemiology and resuscitation effects of cardiopulmonary arrest among hospitalized children and adolescents in Beijing: An observational study. *Resuscitation*. 2013; 84:1685–90. [PubMed: 23974007]
25. Atkins DL, Everson-Stewart S, Sears GK, et al. Epidemiology and outcomes from out-of-hospital cardiac arrest in children: the Resuscitation Outcomes Consortium Epistry-Cardiac Arrest. *Circulation*. 2009; 119:1484–91. [PubMed: 19273724]
26. Nitta M, Iwami T, Kitamura T, et al. Age-specific differences in outcomes after out-of-hospital cardiac arrests. *Pediatrics*. 2011; 128:e812–20. [PubMed: 21890823]
27. Tibballs J, Kinney S. A prospective study of outcome of in-patient paediatric cardiopulmonary arrest. *Resuscitation*. 2006; 71:310–18. [PubMed: 17069956]
28. Matos RI, Watson RS, Nadkarni VM, et al. Duration of cardiopulmonary resuscitation and illness category impact survival and neurologic outcomes for in-hospital pediatric cardiac arrests. *Circulation*. 2013; 127:442–51. [PubMed: 23339874]
29. de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015; 132(18 Suppl 2):S526–42. [PubMed: 26473000]
30. Hoyme DB, Patel SS, Samson RA, et al. Epinephrine dosing interval and survival outcomes during pediatric in-hospital cardiac arrest. *Resuscitation*. 2017; 117:18–23. [PubMed: 28552658]
31. Alzaga-Fernandez AG, Varon J. Open-chest cardiopulmonary resuscitation: past, present and future. *Resuscitation*. 2005; 64:149–56. [PubMed: 15680522]
32. Brooks SC, Anderson ML, Bruder E, et al. Part 6: Alternative Techniques and Ancillary Devices for Cardiopulmonary Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2015; 132(18 Suppl 2):S436–S443. [PubMed: 26472994]
33. Gupta P, Rettiganti M, Jeffries HE, et al. Risk factors and outcomes of in-hospital cardiac arrest following pediatric heart operations of varying complexity. *Resuscitation*. 2016; 105:1–7. [PubMed: 27185218]
34. Lasa JJ, Rogers RS, Localio R, et al. Extracorporeal cardiopulmonary resuscitation (E-CPR) during pediatric in-hospital cardiopulmonary arrest is associated with improved survival to discharge. A report from the American Heart Association’s Get With The Guidelines-Resuscitation (GWTG-R) Registry. *Circulation*. 2016; 133:165–76. [PubMed: 26635402]
35. Nasser BA, Idris J, Mesned AR, Mohamad T, Kabbani MS, Alakfash A. Predictors of cardiopulmonary resuscitation outcome in postoperative cardiac children. *J Saudi Heart Assoc*. 2016; 28:244–8. [PubMed: 27688672]
36. Lopez-Herce J, del Castillo J, Matamoros M, et al. Post return of spontaneous circulation factors associated with mortality in pediatric in-hospital cardiac arrest: a prospective multicenter multinational observational study. *Crit Care*. 2014; 18:607. [PubMed: 25672247]
37. Topjian AA, Clark AE, Casper TC, et al. Early lactate elevations following resuscitation from pediatric cardiac arrest are associated with increased mortality. *Pediatr Crit Care Med*. 2013; 14:e380–7. [PubMed: 23925146]
38. Andersen LW, Berg KM, Saindon BZ, et al. Time to epinephrine and survival after pediatric in-hospital cardiac arrest. *JAMA*. 2015; 314:802–10. [PubMed: 26305650]



**Table 1**

Child Characteristics and Associations with Outcomes

| Characteristic                    | Overall     | Survived to 12 months | P-value <sup>a</sup> | VABS-II decreased by 15 points <sup>b</sup> | P-value <sup>d</sup> | Survived to 12 months with VABS-II 70 <sup>b</sup> | P-value <sup>e</sup> |
|-----------------------------------|-------------|-----------------------|----------------------|---------------------------------------------|----------------------|----------------------------------------------------|----------------------|
| <b>Total</b>                      | 329         | 155/327 (47.4%)       |                      | 93/317 (29.3%)                              |                      | 96/257 (37.4%)                                     |                      |
| <b>Age in years</b>               |             |                       | 0.093                |                                             | 0.244                |                                                    | 0.557                |
| < 1 year                          | 165 (50.2%) | 86/164 (52.4%)        |                      | 48/158 (30.4%)                              |                      | 52/133 (39.1%)                                     |                      |
| 1 – 4 years                       | 77 (23.4%)  | 33/76 (43.4%)         |                      | 24/75 (32.0%)                               |                      | 20/59 (33.9%)                                      |                      |
| 5 – 12 years                      | 48 (14.6%)  | 20/48 (41.7%)         |                      | 15/48 (31.3%)                               |                      | 16/38 (42.1%)                                      |                      |
| > 13 years                        | 39 (11.9%)  | 16/39 (41.0%)         |                      | 6/36 (16.7%)                                |                      | 8/27 (29.6%)                                       |                      |
| <b>Sex</b>                        |             |                       | 0.439                |                                             | 0.716                |                                                    | 0.130                |
| Male                              | 196 (59.6%) | 89/195 (45.6%)        |                      | 54/189 (28.6%)                              |                      | 51/152 (33.6%)                                     |                      |
| Female                            | 133 (40.4%) | 66/132 (50.0%)        |                      | 39/128 (30.5%)                              |                      | 45/105 (42.9%)                                     |                      |
| <b>Race</b>                       |             |                       | 0.870                |                                             | 0.712                |                                                    | 0.266                |
| Asian                             | 9 (2.7%)    | 5/9 (55.6%)           |                      | 4/9 (44.4%)                                 |                      | 4/7 (57.1%)                                        |                      |
| Black or African American         | 97 (29.5%)  | 47/97 (48.5%)         |                      | 26/92 (28.3%)                               |                      | 26/73 (35.6%)                                      |                      |
| White                             | 189 (57.4%) | 86/188 (45.7%)        |                      | 52/183 (28.4%)                              |                      | 53/152 (34.9%)                                     |                      |
| Other/Unknown                     | 34 (10.3%)  | 17/33 (51.5%)         |                      | 11/33 (33.3%)                               |                      | 13/25 (52.0%)                                      |                      |
| <b>Ethnicity</b>                  |             |                       | 0.675                |                                             | 0.661                |                                                    | 0.641                |
| Hispanic or Latino                | 66 (20.1%)  | 30/66 (45.5%)         |                      | 18/65 (27.7%)                               |                      | 18/51 (35.3%)                                      |                      |
| Not Hispanic or Latino            | 245 (74.5%) | 118/244 (48.4%)       |                      | 72/236 (30.5%)                              |                      | 75/193 (38.9%)                                     |                      |
| Unknown                           | 18 (5.5%)   | 7/17 (41.2%)          |                      | 3/16 (18.8%)                                |                      | 3/13 (23.1%)                                       |                      |
| <b>Body Habitus</b>               |             |                       | 0.981                |                                             | 0.723                |                                                    | 0.622                |
| Underweight                       | 67 (20.4%)  | 33/67 (49.3%)         |                      | 20/62 (32.3%)                               |                      | 15/47 (31.9%)                                      |                      |
| Normal/Overweight                 | 205 (62.3%) | 94/203 (46.3%)        |                      | 58/199 (29.1%)                              |                      | 65/167 (38.9%)                                     |                      |
| Obese                             | 52 (15.8%)  | 26/52 (50.0%)         |                      | 15/51 (29.4%)                               |                      | 15/41 (36.6%)                                      |                      |
| Unknown                           | 5 (1.5%)    | 2/5 (40.0%)           |                      | 0/5 (0.0%)                                  |                      | 1/2 (50.0%)                                        |                      |
| <b>Any pre-existing condition</b> | 299 (90.9%) | 139/298 (46.6%)       | 0.380                | 85/291 (29.2%)                              | 0.867                | 85/231 (36.8%)                                     | 0.582                |
| Cardiac condition                 | 220 (66.9%) | 101/219 (46.1%)       | 0.509                | 64/216 (29.6%)                              | 0.867                | 65/176 (36.9%)                                     | 0.837                |
| Respiratory condition             | 109 (33.1%) | 50/108 (46.3%)        | 0.779                | 30/105 (28.6%)                              | 0.833                | 27/79 (34.2%)                                      | 0.483                |
| Neurologic condition              | 105 (31.9%) | 45/104 (43.3%)        | 0.307                | 32/103 (31.1%)                              | 0.639                | 19/59 (32.2%)                                      | 0.351                |
| Gastrointestinal condition        | 100 (30.4%) | 40/99 (40.4%)         | 0.095                | 25/97 (25.8%)                               | 0.355                | 17/68 (25.0%)                                      | 0.014                |

| Characteristic               | Overall     | Survived to 12 months | P-value <sup>a</sup> | VABS-II decreased by 15 points <sup>b</sup> | P-value <sup>a</sup> | Survived to 12 months with VABS-II 70 <sup>b</sup> | P-value <sup>a</sup> |
|------------------------------|-------------|-----------------------|----------------------|---------------------------------------------|----------------------|----------------------------------------------------|----------------------|
| Prenatal condition           | 86 (26.1%)  | 38/86 (44.2%)         | 0.487                | 24/86 (27.9%)                               | 0.733                | 22/58 (37.9%)                                      | 0.918                |
| Pulmonary hypertension       | 20 (6.1%)   | 4/19 (21.1%)          | 0.018                | 4/19 (21.1%)                                | 0.413                | 3/13 (23.1%)                                       | 0.275                |
| Other pre-existing condition | 148 (45.0%) | 64/147 (43.5%)        | 0.206                | 38/140 (27.1%)                              | 0.445                | 37/109 (33.9%)                                     | 0.332                |
| <b>Single Ventricle</b>      | 73 (22.2%)  | 30/73 (41.1%)         | 0.221                | 18/72 (25.0%)                               | 0.358                | 18/58 (31.0%)                                      | 0.258                |

<sup>a</sup>P-values for Body Habitus and Age Category from two-sided Cochran-Armitage test for trend. All other p-values from chi-squared test of no association.

<sup>b</sup>VABS-II is Vineland Adaptive Behavior Scales, Second Edition

Table 2

## Cardiac Arrest Characteristics and Associations with Outcomes

| Characteristic                                          | Overall     | Survived to 12 months | P-value <sup>d</sup> | VABS-II decreased by 15 points <sup>b</sup> | P-value <sup>d</sup> | Survived to 12 months with VABS-II 70 <sup>b</sup> | P-value <sup>d</sup> |
|---------------------------------------------------------|-------------|-----------------------|----------------------|---------------------------------------------|----------------------|----------------------------------------------------|----------------------|
| <b>Total</b>                                            | 329         | 155/327 (47.4%)       |                      | 93/317 (29.3%)                              |                      | 96/257 (37.4%)                                     |                      |
| <b>Primary etiology of cardiac arrest</b>               |             |                       |                      |                                             |                      |                                                    |                      |
| Cardiovascular event <sup>c</sup>                       | 214 (65.0%) | 99/213 (46.5%)        | 0.675                | 59/206 (28.6%)                              | 0.332                | 63/171 (36.8%)                                     | 0.901                |
| Respiratory event                                       | 100 (30.4%) | 50/99 (50.5%)         |                      | 32/97 (33.0%)                               |                      | 29/74 (39.2%)                                      |                      |
| Other                                                   | 15 (4.6%)   | 6/15 (40.0%)          |                      | 2/14 (14.3%)                                |                      | 4/12 (33.3%)                                       |                      |
| <b>Initial cardiac arrest rhythm</b>                    |             |                       |                      |                                             |                      |                                                    |                      |
| Asystole                                                | 24 (7.3%)   | 4/24 (16.7%)          | 0.003                | 3/24 (12.5%)                                | 0.368                | 2/17 (11.8%)                                       | <.001                |
| Bradycardia                                             | 189 (57.4%) | 85/187 (45.5%)        |                      | 53/181 (29.3%)                              |                      | 48/143 (33.6%)                                     |                      |
| Pulseless electrical activity                           | 69 (21.0%)  | 39/69 (56.5%)         |                      | 21/67 (31.3%)                               |                      | 25/58 (43.1%)                                      |                      |
| Ventricular fibrillation or tachycardia                 | 34 (10.3%)  | 22/34 (64.7%)         |                      | 12/33 (36.4%)                               |                      | 20/30 (66.7%)                                      |                      |
| Unknown                                                 | 13 (4.0%)   | 5/13 (38.5%)          |                      | 4/12 (33.3%)                                |                      | 1/9 (11.1%)                                        |                      |
| <b>Duration of chest compressions</b>                   |             |                       |                      |                                             |                      |                                                    |                      |
| Less than or equal to 15 minutes                        | 138 (41.9%) | 78/137 (56.9%)        | 0.012                | 52/129 (40.3%)                              | 0.001                | 51/103 (49.5%)                                     | 0.004                |
| More than 15 to less than or equal to 30 minutes        | 53 (16.1%)  | 23/53 (43.4%)         |                      | 14/53 (26.4%)                               |                      | 11/37 (29.7%)                                      |                      |
| More than 30 minutes                                    | 138 (41.9%) | 54/137 (39.4%)        |                      | 27/135 (20.0%)                              |                      | 34/117 (29.1%)                                     |                      |
| <b>Total number of doses of adrenaline administered</b> |             |                       |                      |                                             |                      |                                                    |                      |
| 0                                                       | 15 (4.6%)   | 11/15 (73.3%)         | 0.003                | 9/14 (64.3%)                                | 0.002                | 8/12 (66.7%)                                       | 0.011                |
| 1                                                       | 38 (11.6%)  | 22/38 (57.9%)         |                      | 14/35 (40.0%)                               |                      | 12/27 (44.4%)                                      |                      |
| 2                                                       | 52 (15.8%)  | 28/51 (54.9%)         |                      | 18/51 (35.3%)                               |                      | 20/43 (46.5%)                                      |                      |
| 3                                                       | 36 (10.9%)  | 20/36 (55.6%)         |                      | 11/31 (35.5%)                               |                      | 12/25 (48.0%)                                      |                      |
| 4                                                       | 31 (9.4%)   | 18/31 (58.1%)         |                      | 10/30 (33.3%)                               |                      | 11/26 (42.3%)                                      |                      |
| More than 4                                             | 156 (47.4%) | 55/155 (35.5%)        |                      | 30/155 (19.4%)                              |                      | 32/123 (26.0%)                                     |                      |
| Unknown                                                 | 1 (0.3%)    | 1/1 (100.0%)          |                      | 1/1 (100.0%)                                |                      | 1/1 (100.0%)                                       |                      |
| <b>Adrenaline Dosing Interval<sup>d</sup></b>           |             |                       |                      |                                             |                      |                                                    |                      |
| No adrenaline recorded                                  | 15 (4.6%)   | 11/15 (73.3%)         | 0.004                | 9/14 (64.3%)                                | 0.022                | 8/12 (66.7%)                                       | 0.005                |
| < 3 min/dose                                            | 77 (23.4%)  | 35/76 (46.1%)         |                      | 23/74 (31.1%)                               |                      | 23/56 (41.1%)                                      |                      |
| 3 – < 5 min/dose                                        | 85 (25.8%)  | 51/85 (60.0%)         |                      | 26/81 (32.1%)                               |                      | 32/66 (48.5%)                                      |                      |

| Characteristic                                               | Overall     | Survived to 12 months | P-value <sup>d</sup> | VABS-II decreased by 15 points <sup>b</sup> | P-value <sup>d</sup> | Survived to 12 months with VABS-II 70 <sup>b</sup> | P-value <sup>d</sup> |
|--------------------------------------------------------------|-------------|-----------------------|----------------------|---------------------------------------------|----------------------|----------------------------------------------------|----------------------|
| 5 < 8 min/dose                                               | 72 (21.9%)  | 25/71 (35.2%)         |                      | 16/70 (22.9%)                               |                      | 14/56 (25.0%)                                      |                      |
| 8 min/dose                                                   | 79 (24.0%)  | 32/79 (40.5%)         |                      | 18/77 (23.4%)                               |                      | 18/66 (27.3%)                                      |                      |
| Unknown                                                      | 1 (0.3%)    | 1/1 (100.0%)          |                      | 1/1 (100.0%)                                |                      | 1/1 (100.0%)                                       |                      |
| <b>Time of arrest<sup>e</sup></b>                            |             |                       | 0.423                |                                             | 0.355                |                                                    | 0.531                |
| Day                                                          | 226 (68.7%) | 110/225 (48.9%)       |                      | 68/220 (30.9%)                              |                      | 68/176 (38.6%)                                     |                      |
| Night                                                        | 103 (31.3%) | 45/102 (44.1%)        |                      | 25/97 (25.8%)                               |                      | 28/81 (34.6%)                                      |                      |
| <b>Day of arrest<sup>f</sup></b>                             |             |                       | 0.774                |                                             | 0.890                |                                                    | 0.758                |
| Weekday                                                      | 272 (82.7%) | 127/270 (47.0%)       |                      | 77/261 (29.5%)                              |                      | 79/209 (37.8%)                                     |                      |
| Weekend                                                      | 57 (17.3%)  | 28/57 (49.1%)         |                      | 16/56 (28.6%)                               |                      | 17/48 (35.4%)                                      |                      |
| <b>Location of arrest within hospital</b>                    |             |                       | 0.962                |                                             | 0.921                |                                                    | 0.514                |
| Emergency department                                         | 43 (13.1%)  | 21/42 (50.0%)         |                      | 13/42 (31.0%)                               |                      | 10/29 (34.5%)                                      |                      |
| Non-intensive care inpatient ward                            | 34 (10.3%)  | 15/34 (44.1%)         |                      | 9/32 (28.1%)                                |                      | 7/27 (25.9%)                                       |                      |
| Intensive care unit (includes intermediate care)             | 202 (61.4%) | 97/201 (48.3%)        |                      | 58/194 (29.9%)                              |                      | 63/159 (39.6%)                                     |                      |
| Operating room                                               | 27 (8.2%)   | 13/27 (48.1%)         |                      | 7/26 (26.9%)                                |                      | 9/20 (45.0%)                                       |                      |
| Other clinical location                                      | 20 (6.1%)   | 8/20 (40.0%)          |                      | 6/20 (30.0%)                                |                      | 7/19 (36.8%)                                       |                      |
| Non-clinical location                                        | 3 (0.9%)    | 1/3 (33.3%)           |                      | 0/3 (0.0%)                                  |                      | 0/3 (0.0%)                                         |                      |
| <b>IV present at the time of arrest</b>                      |             |                       | 0.601                |                                             | 0.702                |                                                    | 0.071                |
| No                                                           | 25 (7.6%)   | 10/25 (40.0%)         |                      | 5/23 (21.7%)                                |                      | 3/20 (15.0%)                                       |                      |
| Yes                                                          | 301 (91.5%) | 143/299 (47.8%)       |                      | 87/291 (29.9%)                              |                      | 93/236 (39.4%)                                     |                      |
| Unable to determine                                          | 3 (0.9%)    | 2/3 (66.7%)           |                      | 1/3 (33.3%)                                 |                      | 0/1 (0.0%)                                         |                      |
| <b>Intubated at the time of arrest</b>                       |             |                       | 0.365                |                                             | 0.085                |                                                    | 0.422                |
| No                                                           | 112 (34.0%) | 56/111 (50.5%)        |                      | 34/106 (32.1%)                              |                      | 33/91 (36.3%)                                      |                      |
| Yes                                                          | 213 (64.7%) | 96/212 (45.3%)        |                      | 56/207 (27.1%)                              |                      | 62/165 (37.6%)                                     |                      |
| Unable to determine                                          | 4 (1.2%)    | 3/4 (75.0%)           |                      | 3/4 (75.0%)                                 |                      | 1/1 (100.0%)                                       |                      |
| <b>Previous ICU admission during current hospitalization</b> |             |                       | 0.253                |                                             | 0.066                |                                                    | 0.284                |
| No                                                           | 270 (82.1%) | 131/268 (48.9%)       |                      | 82/260 (31.5%)                              |                      | 82/211 (38.9%)                                     |                      |
| Yes                                                          | 59 (17.9%)  | 24/59 (40.7%)         |                      | 11/57 (19.3%)                               |                      | 14/46 (30.4%)                                      |                      |
| <b>Number of defibrillation attempts</b>                     |             |                       | 0.935                |                                             | 0.793                |                                                    | 0.278                |
| None                                                         | 260 (79.0%) | 124/259 (47.9%)       |                      | 72/250 (28.8%)                              |                      | 69/199 (34.7%)                                     |                      |
| 1                                                            | 22 (6.7%)   | 9/22 (40.9%)          |                      | 7/21 (33.3%)                                |                      | 7/18 (38.9%)                                       |                      |

| Characteristic                                  | Overall     | Survived to 12 months |                      | VABS-II decreased by 15 points <sup>b</sup> |                      | Survived to 12 months with VABS-II 70 <sup>b</sup> |                      | P-value <sup>d</sup> |
|-------------------------------------------------|-------------|-----------------------|----------------------|---------------------------------------------|----------------------|----------------------------------------------------|----------------------|----------------------|
|                                                 |             | Survived to 12 months | P-value <sup>d</sup> | VABS-II decreased by 15 points <sup>b</sup> | P-value <sup>d</sup> | Survived to 12 months with VABS-II 70 <sup>b</sup> | P-value <sup>d</sup> |                      |
| 2                                               | 23 (7.0%)   | 10/23 (43.5%)         |                      | 7/23 (30.4%)                                |                      | 10/22 (45.5%)                                      |                      |                      |
| 3                                               | 8 (2.4%)    | 4/8 (50.0%)           |                      | 2/8 (25.0%)                                 |                      | 4/8 (50.0%)                                        |                      |                      |
| 4                                               | 6 (1.8%)    | 3/6 (50.0%)           |                      | 1/6 (16.7%)                                 |                      | 2/2 (100.0%)                                       |                      |                      |
| More than 4                                     | 8 (2.4%)    | 5/8 (62.5%)           |                      | 4/8 (50.0%)                                 |                      | 4/7 (57.1%)                                        |                      |                      |
| Unknown                                         | 2 (0.6%)    | 0/1 (0.0%)            |                      | 0/1 (0.0%)                                  |                      | 0/1 (0.0%)                                         |                      |                      |
| <b>Open chest cardiac compressions</b>          |             |                       | 0.058                |                                             | 0.043                |                                                    | 0.036                |                      |
| No                                              | 273 (83.0%) | 122/271 (45.0%)       |                      | 71/263 (27.0%)                              |                      | 73/212 (34.4%)                                     |                      |                      |
| Yes                                             | 56 (17.0%)  | 33/56 (58.9%)         |                      | 22/54 (40.7%)                               |                      | 23/45 (51.1%)                                      |                      |                      |
| <b>ECMO at treatment initiation<sup>g</sup></b> |             |                       | 0.006                |                                             | 0.001                |                                                    | <.001                |                      |
| No                                              | 149 (45.3%) | 82/147 (55.8%)        |                      | 54/140 (38.6%)                              |                      | 51/100 (51.0%)                                     |                      |                      |
| Yes                                             | 180 (54.7%) | 73/180 (40.6%)        |                      | 39/177 (22.0%)                              |                      | 45/157 (28.7%)                                     |                      |                      |

<sup>a</sup>All p-values from chi-squared test of no association

<sup>b</sup>VABS-II is Vineland Adaptive Behavior Scales, Second Edition

<sup>c</sup>Cardiovascular event includes cardiovascular events due congenital heart disease and not due to congenital heart disease

<sup>d</sup>Associations were also examined after excluding the category "No adrenaline recorded." Dosing interval was found to be associated with Survival to month 12 (p=0.039), but not with either VABS-II decreased by 15 points (p=0.43) or Survival with VABS-II 70 (p=0.14).

<sup>e</sup>Day is defined as 7:00 AM to 6:59 PM; night as 7:00 PM to 6:59 AM

<sup>f</sup>Weekend is defined as Monday 12:00 AM to Friday 11:59 PM; weekend as Saturday 12:00 AM to Sunday 11:59 PM

<sup>g</sup>ECMO is extracorporeal membrane oxygenation

**Table 3**

## Logistic Regression Models

| Characteristic                                        | Odds Ratio (95% CI) | P-value |
|-------------------------------------------------------|---------------------|---------|
| <b>Survived to 12 months</b>                          |                     |         |
| Blood lactate (mmol/L)                                | 0.94 (0.89, 0.98)   | 0.008   |
| Initial cardiac arrest rhythm                         |                     | 0.002   |
| Bradycardia                                           | Reference           |         |
| Asystole                                              | 0.09 (0.02, 0.43)   |         |
| Pulseless electrical activity                         | 1.29 (0.68, 2.44)   |         |
| Ventricular fibrillation or tachycardia               | 3.08 (1.25, 7.61)   |         |
| Unknown                                               | 0.70 (0.18, 2.80)   |         |
| Adrenaline doses                                      |                     | 0.026   |
| 4 or fewer                                            | Reference           |         |
| More than 4                                           | 0.52 (0.30, 0.92)   |         |
| Adrenaline dosing interval                            |                     | 0.048   |
| No adrenaline recorded                                | 1.03 (0.23, 4.63)   |         |
| < 3 min/dose                                          | 0.50 (0.24, 1.06)   |         |
| 3 – < 5 min/dose                                      | Reference           |         |
| 5 – < 8 min/dose                                      | 0.42 (0.20, 0.89)   |         |
| 8 min/dose                                            | 0.35 (0.16, 0.75)   |         |
| Open chest compressions performed                     |                     | 0.022   |
| No                                                    | Reference           |         |
| Yes                                                   | 2.21 (1.12, 4.34)   |         |
| <b>VABS-II decreased by 15 points<sup>a</sup></b>     |                     |         |
| Blood lactate (mmol/L)                                | 0.92 (0.88, 0.97)   | 0.003   |
| Open chest cardiac compressions                       |                     | 0.007   |
| No                                                    | Reference           |         |
| Yes                                                   | 2.53 (1.28, 5.00)   |         |
| ECMO at treatment initiation <sup>b</sup>             |                     | 0.030   |
| No                                                    | Reference           |         |
| Yes                                                   | 0.52 (0.29, 0.94)   |         |
| <b>Survived to 12 months with VABS 70<sup>a</sup></b> |                     |         |
| Blood lactate (mmol/L)                                | 0.93 (0.88, 0.99)   | 0.014   |
| Initial cardiac arrest rhythm                         |                     | <.001   |
| Bradycardia                                           | Reference           |         |
| Asystole                                              | 0.13 (0.02, 1.05)   |         |
| Pulseless electrical activity                         | 1.75 (0.86, 3.56)   |         |
| Ventricular fibrillation or tachycardia               | 6.60 (2.40, 18.11)  |         |
| Unknown                                               | 0.33 (0.04, 2.91)   |         |
| Open chest cardiac compressions                       |                     | 0.023   |
| No                                                    | Reference           |         |
| Yes                                                   | 2.46 (1.13, 5.32)   |         |

| Characteristic                            | Odds Ratio (95% CI) | P-value |
|-------------------------------------------|---------------------|---------|
| ECMO at treatment initiation <sup>b</sup> |                     | 0.002   |
| No                                        | Reference           |         |
| Yes                                       | 0.34 (0.17, 0.67)   |         |

<sup>a</sup>VABS-II is Vineland Adaptive Behavior Scales, Second Edition

<sup>b</sup>ECMO is extracorporeal membrane oxygenation

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript